Jing Wu

3.4k total citations
171 papers, 2.3k citations indexed

About

Jing Wu is a scholar working on Economics and Econometrics, General Health Professions and Epidemiology. According to data from OpenAlex, Jing Wu has authored 171 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Economics and Econometrics, 25 papers in General Health Professions and 25 papers in Epidemiology. Recurrent topics in Jing Wu's work include Health Systems, Economic Evaluations, Quality of Life (48 papers), Pharmaceutical Economics and Policy (17 papers) and Healthcare Policy and Management (14 papers). Jing Wu is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (48 papers), Pharmaceutical Economics and Policy (17 papers) and Healthcare Policy and Management (14 papers). Jing Wu collaborates with scholars based in China, Canada and United States. Jing Wu's co-authors include Xiaoning He, Jianqiang Yu, Shitong Xie, Emmanuela Gakidou, Yuanli Liu, Yu‐Xiang Li, Guangjiang Shi, Yawen Jiang, Yang Niu and Tao Sun and has published in prestigious journals such as The Lancet, The Journal of Immunology and PLoS ONE.

In The Last Decade

Jing Wu

145 papers receiving 2.3k citations

Peers

Countries citing papers authored by Jing Wu

Since Specialization

Citations

This map shows the geographic impact of Jing Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jing Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jing Wu more than expected).

Fields of papers citing papers by Jing Wu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jing Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jing Wu. The network helps show where Jing Wu may publish in the future.

Co-authorship network of co-authors of Jing Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Jing Wu. A scholar is included among the top collaborators of Jing Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jing Wu. Jing Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	How Does Disease Severity Affect Clinical Outcomes and Economic Burden of Patients with COPD —— A Retrospective Population-Based Cohort Study in Tianjin, China 2025 ·International Journal of COPD ·(unknown), Ke Huang, Xiaoning He, Jiahui Zhang, Ting Yang, Jing Wu	0
2	Assessing the economic burden and health-related quality of life in chinese patients with fibrodysplasia ossificans progressiva: a questionnaire survey analysis 2025 ·Orphanet Journal of Rare Diseases ·(unknown), Xiaoning He, Wei Wu, Xin Yan, Qingnan Li, Lei Song, Kexin Li, Jing Wu	0
3	Determinants of Transitional Care Utilization Among Older Adults with Chronic Diseases: An Analysis Based on Andersen’s Behavioral Model 2025 ·Clinical Interventions in Aging ·Yuanyuan Ma, Tingting Wu, Li Ping Wang, (unknown), Jing Wu, (unknown)	0
4	Psychometric performance of EQ-5D-5L and SF-6Dv2 in patients with lymphoma in China 2024 ·The European Journal of Health Economics ·(unknown), Jing Li, Zhuxin Mao, Zitong Wang, Jing Wu, Nan Luo, Peng Liu, Pei Wang	5
5	Hearing Loss and Cognitive Impairment Among Community-Dwelling Older Adults — Liaoning, Henan, and Guangdong Provinces, China, 2019–2020 2024 ·China CDC Weekly ·Shige Qi, (unknown), (unknown), (unknown), Ran An, Lu Cui, Han Zhang, Jing Wu	0
6	Efficacy, Safety, and Treatment Burden of Aflibercept 2 mg and Ranibizumab in Retinal Vein Occlusion: A Systematic Review and Meta-analysis 2024 ·Ophthalmology and Therapy ·Jing Wu, (unknown), (unknown), (unknown), Zhe Xu, Hong Yan	1
7	Testing the unintended cost effects of health policies for generic substitutions: the case of China’s National Volume-Based Procurement (NVBP) policy 2024 ·Health Policy and Planning ·Boya Zhao, Jing Wu, Xing Lin Feng	1
8	The generic version of China Health Related Outcomes Measures (CHROME-G): psychometric testing and comparative performance with the EQ-5D-5L and SF-6Dv2 among the Chinese general population 2024 ·BMC Public Health ·Shitong Xie, Jing Wu, (unknown), Xiaoning He, Kun Zhao, Feng Xie, (unknown)	2
9	Evaluation of measurement properties of the Impact of Weight on Quality of Life-Lite (IWQOL-Lite) instrument among Chinese overweight and obese populations 2024 ·Health and Quality of Life Outcomes ·(unknown), Tianqi Hong, (unknown), Shitong Xie, Jing Wu	0
10	HPR51 Should Volume-Based Procurement Price of Comparator be Referenced for Innovative Drugs in National Reimbursement Drug List Negotiation in China? 2023 ·Value in Health ·Jing Wu, (unknown), Jian Ming, Shuli Qu, Tang Wei, Liguo Zhu, Chen Jing	1
11	Finding Influential Subjects in a Network Using a Causal Framework 2023 ·Biometrics ·Youjin Lee, Ashley Buchanan, Elizabeth L. Ogburn, Samuel R. Friedman, M. Elizabeth Halloran, Natallia Katenka, Jing Wu, Georgios K. Nikolopoulos	0
12	Comparison of the measurement properties of the EQ-5D-5L and SF-6Dv2 among overweight and obesity populations in China 2023 ·Health and Quality of Life Outcomes ·Shitong Xie, Meixuan Li, (unknown), Tianqi Hong, (unknown), Jing Wu	4
13	Cost Effectiveness of the First‐in‐Class ARNI (Sacubitril/Valsartan) for the Treatment of Essential Hypertension in a Chinese Setting 2022 ·PharmacoEconomics ·(unknown), Xiaoning He, Jing Wu	4
14	Differences in Lung Cancer Treatment Preferences Among Oncologists, Patients and Family Members: A Semi-Structured Qualitative Study in China 2021 ·Patient Preference and Adherence ·Xiaoning He, (unknown), Jing Wu, Song Xu, Xiangli Jiang, Ziping Wang, Shucai Zhang, Feng Xie	6
15	Dietary Patterns and the Risk of Prediabetes in Taiwan: A Cross-Sectional Study 2020 ·Nutrients ·(unknown), (unknown), I‐Shiang Tzeng, Chan‐Yen Kuo, Ching‐Feng Cheng, Jing Wu, Shwu‐Huey Yang	7
16	Cost-effectiveness and value-based prices of the 9-valent human papillomavirus vaccine for the prevention of cervical cancer in China: an economic modelling analysis 2019 ·BMJ Open ·Yawen Jiang, Weiyi Ni, Jing Wu	13
17	EQ-5D-3L Decrements By Diabetes Complications and Comorbidities in China 2018 ·Value in Health ·(unknown), Lizheng Shi, Jing Wu, (unknown)	2
18	Healthcare Resource Utilization And Cost Of Patients With Acute Coronary Syndromes In Tianjin, China 2017 ·Value in Health ·Yaran Wang, Hongliang Cong, Chengzhi Lu, (unknown), Jing Wu	1
19	Increasing Anti-Infective Drug Expenditure in Tianjin, China: A Decomposition Analysis 2013 ·Value in Health Regional Issues ·Jing Wu, Yue Ning, (unknown)	7
20	Impact of retinol binding protein 4 polymorphism on rosiglitazone response in Chinese type 2 diabetic patients. 2011 ·PubMed ·Fang Zhou, Qiong Huang, (unknown), Ji‐Ye Yin, Jing Wu, Hong-Hao Zhou, Zhicheng Gong, Zhaoqian Liu	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact